Sage Therapeutics price target raised to $30 from $26 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on Sage Therapeutics to $30 from $26 and keeps a Neutral rating on the shares. The firm, which increased its pipeline value given the potential for ‘718 and ‘324 to expand the commercial opportunity with several trial readouts in 2024, will continue to look for color on expectations for the cadence of the Zurzuvae launch and updates on the pipeline programs, the analyst tells investors.